Detection of structural DNA variation from next generation sequencing data: a review of informatic approaches

Cancer Genetics
Haley J Abel, Eric J Duncavage

Abstract

Next generation sequencing (NGS), or massively paralleled sequencing, refers to a collective group of methods in which numerous sequencing reactions take place simultaneously, resulting in enormous amounts of sequencing data for a small fraction of the cost of Sanger sequencing. Typically short (50-250 bp), NGS reads are first mapped to a reference genome, and then variants are called from the mapped data. While most NGS applications focus on the detection of single nucleotide variants (SNVs) or small insertions/deletions (indels), structural variation, including translocations, larger indels, and copy number variation (CNV), can be identified from the same data. Structural variation detection can be performed from whole genome NGS data or "targeted" data including exomes or gene panels. However, while targeted sequencing greatly increases sequencing coverage or depth of particular genes, it may introduce biases in the data that require specialized informatic analyses. In the past several years, there have been considerable advances in methods used to detect structural variation, and a full range of variants from SNVs to balanced translocations to CNV can now be detected with reasonable sensitivity from either whole genome or t...Continue Reading

References

Oct 12, 2004·Biostatistics·Adam B OlshenMichael Wigler
Jan 19, 2006·Nature Reviews. Genetics·Lars FeukStephen W Scherer
Jul 1, 2006·Genome Research·Jennifer L FreemanCharles Lee
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaUNKNOWN Cancer and Leukemia Group B
Mar 17, 2007·Science·Jonathan SebatMichael Wigler
Jul 27, 2007·Hematology·Marco Wiltgen, Gernot P Tilz
May 7, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistThomas J Lynch
Jan 27, 2009·Cancer Genetics and Cytogenetics·Terezinha de Jesus Marques-SallesMaria Luiza Macedo Silva
Mar 10, 2009·BMC Bioinformatics·Chao Xie, Martti T Tammi
Jun 10, 2009·Bioinformatics·Heng LiUNKNOWN 1000 Genome Project Data Processing Subgroup
Aug 7, 2009·Genome Research·Seungtai YoonJonathan Sebat
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Jan 19, 2010·Bioinformatics·Heng Li, Richard Durbin
Jun 10, 2010·Bioinformatics·Fereydoun HormozdiariS Cenk Sahinalp
Oct 29, 2010·Genome Research·Cornelis A AlbersRichard Durbin
Apr 21, 2011·JAMA : the Journal of the American Medical Association·John S WelchRichard K Wilson
Jul 27, 2011·BMC Genomics·Zhengdong D ZhangMark Gerstein
Aug 11, 2011·Bioinformatics·Jarupon Fah SathirapongsasutiStanley F Nelson
Sep 29, 2011·Nature Biotechnology·Michael J ClarkMichael Snyder
Mar 16, 2012·The New England Journal of Medicine·Matthew J WalterTimothy A Graubert
Mar 20, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Eric J DuncavageJohn D Pfeifer
Apr 5, 2012·Bioinformatics·Jason LiKylie L Gorringe
May 16, 2012·Genome Research·Niklas KrummEvan E Eichler
Jun 5, 2012·The Journal of Molecular Diagnostics : JMD·Colin C PritchardTom Walsh
Sep 18, 2012·Cell·Ramaswamy GovindanRichard K Wilson
Oct 9, 2012·American Journal of Human Genetics·Menachem FromerShaun M Purcell
Feb 13, 2013·BMC Bioinformatics·Kaushalya C AmarasingheSaman K Halgamuge
Feb 28, 2013·BMC Genomics·Dominik GrimmKarsten Borgwardt

❮ Previous
Next ❯

Citations

Feb 6, 2016·The Journal of Molecular Diagnostics : JMD·Martina I LefterovaCurt Scharfe
Jan 12, 2016·Seizure : the Journal of the British Epilepsy Association·Zhi-dong CenWei Luo
Jan 29, 2016·BMC Genomics·Feifei HeHuaiqiu Zhu
Oct 28, 2014·Cancer·Ian S HagemannRamaswamy Govindan
Mar 17, 2015·Journal of Surgical Oncology·Stephen M SmithO Hans Iwenofu
Apr 23, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M Heuckmann, R K Thomas
Aug 20, 2015·Human Genomics·Mohammad Shabbir HasanLiqing Zhang
May 13, 2014·The Journal of Molecular Diagnostics : JMD·Haley J AbelEric J Duncavage
Oct 10, 2014·Journal of Human Genetics·Toshifumi SuzukiNaomichi Matsumoto
Jul 30, 2016·Archives of Pathology & Laboratory Medicine·Ian S Hagemann
Aug 10, 2016·Nature Methods·Ira W DevesonTim R Mercer
Feb 27, 2017·Clinical and Experimental Immunology·A-K KienzlerS Y Patel
Oct 19, 2017·TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·Aria DolatabadianJacqueline Batley
Sep 15, 2018·Current Protocols in Human Genetics·Chengsheng ZhangCharles Lee
Feb 28, 2019·Science China. Life Sciences·José Ranz, Bryan Clifton
May 12, 2020·PLoS Genetics·Marina Brasó-VivesDavid Juan
May 23, 2015·The Korean Journal of Internal Medicine·Seon-Hee YimYeun-Jun Chung
Jan 31, 2017·Nucleic Acids Research·Richard MeierJeremy Chien
Jun 18, 2017·Frontiers in Cardiovascular Medicine·Marlin ToumaYibin Wang
Oct 15, 2019·Frontiers in Genetics·Deborah WeighillDaniel Jacobson
Mar 11, 2017·Breast Cancer Research and Treatment·Beth CrawfordLaura van 't Veer
Dec 18, 2019·International Journal of Neonatal Screening·Julia C van CampenAnn Dalton
Jun 21, 2020·European Journal of Human Genetics : EJHG·José Marcos Moreno-CabreraBernat Gel
Feb 24, 2021·The Journal of Molecular Diagnostics : JMD·Jeroen van den AkkerScott Topper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.